FDA granted pre-market approval for Zephyr Valve.
2 reports, 1 independent
Updated Aug 1
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted pre-market approval for Zephyr Valve.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Pulmonx appointed Steve Williamson as CEO and expanded treatment centers for Zephyr Valve.Sub-event
- Strong adoption of Zephyr valves drove revenue increase for Pulmonx.Sub-event
FDA granted pre-market approval for Zephyr Valve.1 source
Keep exploring
The entities involved
- FDA
-
Pulmonx (United States)
company in Redwood City, United States
Nothing else this week.
Related events
- A product was launched in the U.S. market following FDA involvement.
- FDA and Pfizer are seeking regulatory approval for their products.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- The FDA and Intellia Therapeutics are preparing a regulatory filing for product approval.
- FDA approval enables commercial opportunity involving CBRE Group.
Coverage
Newest first; wire copies grouped- GlobeNewswirePulmonx to Participate in September Investor Conferences REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in mi